Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel antiviral therapeutics, today announced a $5 million investment from ...